Summit Global Investments Sells 7,390 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Summit Global Investments lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 48.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 7,752 shares of the specialty pharmaceutical company’s stock after selling 7,390 shares during the quarter. Summit Global Investments’ holdings in ANI Pharmaceuticals were worth $494,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ANIP. Vanguard Group Inc. grew its position in ANI Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after purchasing an additional 17,460 shares during the last quarter. Rubric Capital Management LP grew its holdings in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after purchasing an additional 277,989 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after purchasing an additional 33,359 shares during the period. Global Alpha Capital Management Ltd. boosted its stake in ANI Pharmaceuticals by 10.8% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after buying an additional 56,900 shares during the period. Finally, Ranger Investment Management L.P. boosted its stake in ANI Pharmaceuticals by 1.8% during the fourth quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after buying an additional 7,769 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded down $0.17 during trading on Wednesday, hitting $61.02. 155,047 shares of the company were exchanged, compared to its average volume of 179,589. The company has a market cap of $1.28 billion, a price-to-earnings ratio of 38.24 and a beta of 0.75. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The firm’s fifty day moving average price is $61.93 and its 200 day moving average price is $63.56. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.95 and a quick ratio of 3.12.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The business had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same quarter in the previous year, the company posted $1.06 EPS. The business’s revenue was up 18.5% on a year-over-year basis. On average, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.3 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $64.41, for a total transaction of $1,288,200.00. Following the completion of the transaction, the senior vice president now owns 213,226 shares of the company’s stock, valued at approximately $13,733,886.66. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, COO Muthusamy Shanmugam sold 14,257 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the sale, the chief operating officer now owns 635,363 shares in the company, valued at approximately $40,129,527.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $64.41, for a total value of $1,288,200.00. Following the sale, the senior vice president now owns 213,226 shares of the company’s stock, valued at approximately $13,733,886.66. The disclosure for this sale can be found here. Insiders sold a total of 93,992 shares of company stock valued at $5,897,630 in the last 90 days. 12.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ANIP shares. Guggenheim reissued a “buy” rating and issued a $77.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. Finally, Truist Financial cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $82.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.